Concepedia

Jiangdian Wang

JW

Statistics

Publications

8

Citations

1.2K

H-Index

8

Active since

2016

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Aichi Cancer Center

Sheba Medical Center

Yale Cancer Center

National Cancer Center Hospital East

Jiangdian Wang is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, radiation oncology, and cancer therapeutics.

Top concepts

Publications per year

2016–2019

8

Publications

8

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

Karina Kulangara, Nancy R. Zhang, Ellie Corigliano et al. · Archives of Pathology & Laboratory Medicine · 2018 · 514 citations · Full text

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

Yung‐Jue Bang, Yoon‐Koo Kang, Daniel V.T. Catenacci et al. · Gastric Cancer · 2019 · 242 citations · Full text

KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.

Charles S. Fuchs, Toshihiko Doi, Raymond Woo-Jun Jang et al. · Journal of Clinical Oncology · 2017 · 173 citations

, , +13

Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.

Hyun Cheol Chung, Jan H.M. Schellens, Jean‐Pierre Delord et al. · Journal of Clinical Oncology · 2018 · 99 citations

, , +20

KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.

Yung‐Jue Bang, Kei Muro, Charles S. Fuchs et al. · Journal of Clinical Oncology · 2017 · 73 citations

, , +14

1–5 of 8